In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Ocular Therapeutix Inc’s stock clocked out at $6.50, up 9.70% from its previous closing price of $5.93. In other words, the price has increased by $9.70 from its previous closing price. On the day, 2.93 million shares were traded.
Ratios:
To gain a deeper understanding of OCUL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.59 and its Current Ratio is at 10.66. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.23.
On June 20, 2024, TD Cowen Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $7 to $11.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 24 ’25 when Dugel Pravin sold 21,475 shares for $6.87 per share. The transaction valued at 147,533 led to the insider holds 3,520,318 shares of the business.
Heier Jeffrey S. sold 3,061 shares of OCUL for $21,029 on Feb 24 ’25. The Chief Scientific Officer now owns 265,998 shares after completing the transaction at $6.87 per share. On Feb 24 ’25, another insider, Kaiser Peter, who serves as the Chief Development Officer of the company, sold 3,009 shares for $6.87 each. As a result, the insider received 20,672 and left with 210,078 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 16.04 while its Price-to-Book (P/B) ratio in mrq is 3.25.
Stock Price History:
Over the past 52 weeks, OCUL has reached a high of $11.77, while it has fallen to a 52-week low of $4.06. The 50-Day Moving Average of the stock is -16.99%, while the 200-Day Moving Average is calculated to be -21.12%.
Shares Statistics:
A total of 157.75M shares are outstanding, with a floating share count of 132.39M. Insiders hold about 15.79% of the company’s shares, while institutions hold 73.34% stake in the company.
Earnings Estimates
The company has 3.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.26 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$1.08 and -$1.35 for the fiscal current year, implying an average EPS of -$1.22. EPS for the following year is -$1.18, with 3.0 analysts recommending between -$1.06 and -$1.3.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $17.22M. It ranges from a high estimate of $17.9M to a low estimate of $16.57M. As of the current estimate, Ocular Therapeutix Inc’s year-ago sales were $14.77MFor the next quarter, 7 analysts are estimating revenue of $17.96M. There is a high estimate of $18.5M for the next quarter, whereas the lowest estimate is $17.37M.
A total of 8 analysts have provided revenue estimates for OCUL’s current fiscal year. The highest revenue estimate was $79.1M, while the lowest revenue estimate was $69.49M, resulting in an average revenue estimate of $72.01M. In the same quarter a year ago, actual revenue was $63.72MBased on 7 analysts’ estimates, the company’s revenue will be $82.32M in the next fiscal year. The high estimate is $100M and the low estimate is $72.3M.
